Report Overview

The Australia Anti-Acne Drug market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Acne is a very common skin condition. It causes spots and painful bumps on the skin. It is most noticeable on the face, but can also appear on the back, shoulders, and buttocks. Severe acne can cause scarring. Acne usually starts in puberty, but it affects adults too. Acne will usually go away on its own, but it can take many years. Some treatments can help clear acne more quickly. Over-the-counter treatments can help with mild acne. Ask a pharmacist for advice on which treatment could help and how long you will have to use it. You should not expect to see results for several weeks, even a couple of months. If over-the-counter treatments do not help after 6 to 8 weeks, treatments are available on prescription. Acne is a common condition that is associated with significant physical and psychological morbidity. It is so common it can be considered almost universal in teenagers, with a prevalence of 93.3% in people aged 1618 years in Australia. Other international studies have shown a prevalence of 85% in people aged 1224 years, and of 64% and 43% in those aged 2029 years and 3039 years, respectively. Acne can be considered a chronic disease.



Market Drivers

An increase in prevalence and severity of acne diseases is the major factor that contributes toward the growth of the acne medication market. Acne vulgaris is the most common skin problem amongst the teenaged population, with women being affected at higher rates than men. Moreover, other factors that fuel the market include an unhealthy urban lifestyle and the presence of robust acne medications in the pipeline. However, side-effects associated with the use of acne medications and the presence of alternative treatments impede the market growth. Conversely, the development of effective medications with lesser side effects and high market potential in untapped emerging economies is expected to provide lucrative growth opportunities for the market growth. Various factors such as fluctuating hormone levels, unhygienic lifestyle, and excessive production of oil from sebaceous glands have increased the prevalence of acne, thereby positively affecting the market growth.

Type of Acne Medication

Topical therapies dominated the market in 2017 by route of administration. Retinoids, antibiotics, BPO, salicylic acid, and azelaic acid are administered topically for mild-to-moderate acne as well as maintenance therapy. Oral medications are recommended as systemic therapies after topical treatments fail to evoke a response.

Treatment of severely inflamed or cystic acne may require cortisone injections. The emergence of biologics is likely to fuel the growth of injectables. Gevokizumab (Novartis/XOMA), RA-18C3 (XBiotech), and CJM112 (Novartis) are investigational monoclonal antibodies for acne treatment. All three candidates involve a subcutaneous mode of injection.